Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Measures relative activity in the regenerative therapy space on a quarterly basis
February 28, 2017
By: Kristin Brooks
Managing Editor, Contract Pharma
Cryoport, a cryogenic logistics services provider for the life sciences, has launched the Cryoport Biotech Regenerative Therapy Activity Index (the “CoBRA Index”) designed to quantify the activity in the development and clinical trials of regenerative therapies in the U.S., and acts as a means to help evaluate investment in the space. Regenerative therapies include various technologies and therapeutic approaches, the majority being cell and gene therapies to treat a wide variety of diseases from hemophilia to cancer. Each of these clinical programs follow complex procedures which are initiated with patient recruitment for trials, pre-treatment medical procedures, manufacturing and product released via complex analytical testing and concluding with patient dosing. The CoBRA Index measures and distills the data from the flow of the processes against clinical trials and provides a view of the flow of therapy progression within the regenerative medicine space. Consistent or accelerating activity generates larger values which are aggregated into the index number. Jerrell Shelton, chief executive officer of Cryoport, said, “Cryoport, as the industry leading provider of cryogenic logistics solutions to the Regenerative Therapy industry, has a unique view, in fact, a virtual real-time insight into the progress of this industry. We created the CoBRA Index to provide industry participants and those following the industry with valuable activity and trend information at a time when the industry is reaching an inflection point with many therapies approaching commercialization.” The CoBRA Index draws upon data generated from the regenerative medicine industry since 1Q15. In 4Q16, the CoBRA Index increased approximately 4% to 169, compared with 162 in 3Q16. This compares to 36% growth in the index in 3Q16 against 2Q16. According to the company, existing regenerative medicine trials represent 94% of current pharmaceutical research. The outlook remains strong as the first CAR-T program has been filed for FDA approval and five more regenerative therapies have indicated an intent to file for commercial approval in 2017. As of October, 2016, there has been more than $17 billion invested in the development of regenerative therapies. It is estimated that regenerative therapies will generate more than $50 billion in annual revenues by 2021 and $250 billion by 2025.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !